Michael Paul and the work between the breakthroughs

A company with two people can fit around a small table. A company with 135 needs an organization. Between those two numbers lie the decisions that rarely make it into a founder’s introduction: whom to hire, which promises to make, how to pay for the next stretch of work. Michael S. Paul spent 14 years in that interval at Lineagen. The interval is a useful place to begin his story.

Paul co-founded the Salt Lake City company in 2006 and remained its president, chief executive, and a director through its acquisition in 2020. Today he is CEO and president of MARAbio. Read only the titles and his career looks tidy. Look at what those jobs required and a different picture emerges: a scientist repeatedly taking responsibility for the commercial machinery around an idea.

The 2015 workplace photograph catches him wearing a headset at a desk, with books and framed pictures behind him. It is an ordinary office scene, and a useful companion to the numbers. The growing company still required a person at a desk, talking to someone and working through the day.

There is a certain romance to invention. Payroll has less of a fan club. Yet Paul’s working life has repeatedly brought the two together. His background includes university technology transfer, intellectual property, venture investing, business development, and company leadership. Those are separate professions on a conference badge. In a young business, they have a habit of arriving on the same afternoon.

The education after the doctorate

Paul earned his bachelor’s degree at Colby College and his doctorate in molecular biology and biochemistry at the University of Utah. His education gave him a scientific foundation; his subsequent work put him among people deciding what could be built around scientific knowledge. At Utah’s Technology Transfer Office, he helped market university inventions to industry. That role placed him at the point where an academic result begins encountering commercial questions.

The sequence matters. Technology transfer requires a conversation between people with different incentives and different vocabularies. A researcher can explain why an idea is interesting. A prospective partner wants to understand what it can do, how it is protected, and what remains to be developed. Paul’s early work put him inside that conversation, before he became the executive expected to sustain it.

He also became a licensed patent agent with the United States Patent and Trademark Office. Later roles included strategic development and intellectual property management at NPS Pharmaceuticals, business development at Huntsman Biotechnology Corporate, and president and chief operating officer of Lineagen Research Corporation. His experience also included venture partner roles at vSpring Capital and Mesa Verde Venture Partners. Science, ownership, money, management: the subjects kept changing, while the practical problem of bringing an invention into commercial use remained.

Fourteen years is a long meeting

Lineagen became the extended test of that background. Starting in 2006, Paul held the founder’s responsibilities alongside the CEO’s. He stayed through the company’s growth and eventual sale. Fourteen years gives the story a different rhythm from the familiar account of a startup appearing, attracting money, and disappearing into an acquisition announcement. This was a substantial part of a working life.

The people who joined him are part of that story. Some leaders accepted delayed or reduced salaries to work at Lineagen. That detail makes recruitment tangible. Joining a small company can mean accepting uncertainty about the company and about one’s own compensation. A founder asking for that commitment has to offer a reason that survives the arrival of ordinary bills.

By the end of Paul’s tenure, the company had grown from two people to 135. It had raised more than $60 million in venture capital and venture debt financing. These figures describe different kinds of work. Hiring builds capacity. Financing buys time and carries obligations. Neither number explains every decision, but together they establish the scale of the organization he helped assemble.

In 2015, Lineagen announced $19.8 million in fundraising, comprising a $15.8 million Series C round and a $4 million credit facility. HealthQuest Capital led the equity round with participation from Petra Capital Partners and Mountain Group Partners, alongside existing investors. Silicon Valley Bank provided the credit facility. For Paul, the milestone involved both bringing new financial partners into the company and continuing relationships with existing ones.

The unromantic question: when do we get paid?

One revealing episode concerned revenue collection. Lineagen had relied on an outside billing provider and lacked sufficient visibility into the status of its claims. The difficulty was prosaic and consequential: the company could do its work and still wait a very long time for the corresponding payment. An enterprise can have an interesting product and a distinctly uninteresting bank balance.

Paul argued for bringing billing and collections inside the business. “It was very important for us to internalize our revenue collections and our billing efforts so we had more control over our future.” The sentence is unusually useful as a glimpse of an executive’s priorities. Control over the future, in this instance, meant understanding the present whereabouts of money already earned.

With AdvancedMD’s software and its existing internal resources, the company reported that monthly collections increased approximately threefold. The figure describes collections after an operational change; it measures payments received and is separate from overall revenue growth. Its significance is the attention it shows to the mechanisms of running a business. Paul was discussing the tools that let staff follow a payment through a process. The glamorous founder photograph seldom includes that screen.

“It is time to get to work.”

Michael Paul / August 2020

An acquisition with a next morning

In August 2020, Bionano Genomics acquired Lineagen. The announced consideration was approximately $9.6 million, involving shares, cash, and assumed liabilities. It is a transaction figure, with a specific structure. It says nothing by itself about Paul’s personal proceeds or any individual investor’s return. The distinction keeps the story at the level of what actually happened to the company.

Paul became Bionano’s chief strategy officer at the time of the transaction. The acquisition announcement placed him alongside Bionano CEO Erik Holmlin in describing the combination. His own statement closed with a compact instruction: “It is time to get to work.” After 14 years, even the exit came with a next morning.

The phrase suits the career’s continuity. Lineagen had moved from founding through capital raising and expansion into another organization. Paul’s responsibilities moved with it. The work of combining businesses begins after an agreement has been signed, when people have to turn the announced rationale into something they can actually operate together.

A new desk, familiar responsibilities

MARAbio announced Paul’s appointment as CEO in April 2023. He succeeded James Woody, who continued as vice chairman. Founder Judy Van de Water remained central to the company, and Paul’s appointment statement emphasized continuing to work with both of them. He arrived as an executive joining an existing enterprise, with its own founder, board, and history.

That distinction adds another dimension to his experience. At Lineagen, he had been present at the beginning. At MARAbio, he took responsibility for a company already established by other people. The job brought a familiar commercial challenge into a different set of relationships. He had to lead alongside people whose contributions preceded his arrival.

In October 2024, MARAbio announced an initial $19 million Series A financing led by MAK Capital One. Michael A. Kaufman and Craig Nemiroff of MAK were to join the board. For Paul, another financing milestone came with new participants in company governance. Capital raising changes the bank account and the room in which the next decisions are discussed.

His work also reaches other boardrooms. Seek Labs appointed him to its board effective March 18, 2024. CEO Jared Bauer highlighted his experience in innovation, management, and commercialization. Paul’s announcement emphasized collaboration with the board and management team. Alongside his executive role, he was taking a seat from which to help another company consider its direction.

Trust has a place on the agenda

The institutional side of Paul’s career extends into Utah’s wider business community. He served as vice chairman of the Utah Technology Council and received a gubernatorial appointment to the steering committee of the Utah Technology Industry Commission. In 2018, he was an EY Entrepreneur of the Year regional finalist. Those roles and recognitions connect the individual company builder to the state’s network of entrepreneurs, investors, and public officials.

A more personal thread appeared in his December 2025 conversation on Imperfect Leaders. The discussion explored trust, honesty, and a leader’s willingness to be vulnerable. It also identified Patrick Lencioni as an influence on Paul’s thinking about leadership. After the financing totals and job titles, this is a useful change of scale: the question becomes how people behave in a room together.

The trust theme gives a human context to the earlier recruiting detail. People who accept uncertainty need candid conversations about it. An organization growing beyond its founders also needs room for colleagues to speak and exercise judgment. Paul’s discussion of leadership places those relationships alongside the formal work of strategy and finance.

His career can be plotted in a few dates: a company founded in 2006, an acquisition in 2020, a new chief executive appointment in 2023, another board appointment in 2024. The distance between those dates contains most of the work. Paul’s story lives there, among the people, commitments, and practical decisions that give an invention a company to belong to.